Phase III Study of AK112 for NSCLC Patients
← catalyst calendarSponsored by Summit Therapeutics (industry) · SMMT — their whole pipeline →. With Akeso.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
420actual
Sites
74
Countries
Canada, France, Italy +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-05-04 | actual | When the study began enrolling |
| Primary completion | 2025-04-12 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-05-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-Squamous Non-small Cell Lung Cancer
Interventions
- Drug: AK112 Injection — also filed as Pemetrexed, Carboplatin
- Drug: Placebo Injection — also filed as Pemetrexed, Carboplatin
Primary outcomes
what the primary-completion date above is the date OFProgression-free survival (PFS)
measured Up to 2 years
Overall Survival (OS) in the ITT population
measured Up to 2 years
Permalink · SMMT's whole pipeline · Catalyst calendar · Every registered study · What changed